The single-dose pharmacokinetics of cefsulodin were evaluated in 12 patients with cystic fibrosis. Each patient received 3 g of cefsulodin intravenously over 30 min. Multiple plasma and urine samples were obtained during the 6-h study period for the determination of cefsulodin. Pharmacokinetic parameters were determined by model-independent methods. Mean values for t1/2, Vs,, and CLp were 1.53 h, 0.242 liters/kg, and 117.3 ml/min per 1.73 m2, respectively. Six-hour urine recovery revealed 73.2% of the administered dose with a corresponding cefsulodin urinary clearance of 75.1 ml/min. These pharmacokinetic data in patients with cystic fibrosis appear consistent with data reported for unaffected individuals.
Patients .12 years of age with cystic fibrosis were eligible for enrollment in this study. The study protocol was approved by the Institutional Review Board for Human Subject Investigation of the University Hospitals of Cleveland. Written, informed consent was obtained from each patient or parent or both. Before drug administration, each patient underwent a complete physical examination and had a laboratory evaluation which included electrolyte analysis, tests of liver and renal function, urinalysis, complete blood count with differential, prothrombin and partial thromboplastin times, and Coomb's test.
Each patient received a 3-g intravenous dose of sodium cefsulodin (Abbott Laboratories, North Chicago, Ill.; lot 37011AR) dissolved in 50 ml of 5% dextrose in water. This dose was chosen because it was the highest for which safety data were available at the time of the study. Blood samples (3 ml) were collected in heparinized tubes at 0, 0.5, 0.75, 1, 1.5, 2, 4, and 6 h after the initiation of a 30-min infusion. Blood samples were placed on ice immediately and centrifuged within 1 h of collection. An equal volume of 1 M potassium phosphate (pH 6.0) was added to each plasma sample to protect against hydrolysis (5) .
Patients were asked to void before drug administration, and all urine excreted during the 6-h study period was collected as 2-h aliquots in iced containers. Urine samples were measured, buffered, and immediately frozen. Plasma and urine samples were frozen at -70°C until analyzed.
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Under these conditions, plasma and urine cefsulodin standards were stable for at least 90 days. All samples were analyzed within 7 days of collection.
Cefsulodin concentrations in plasma and urine were determined by high-pressure liquid chromatography. Our method is a modification of the technique described by Granneman and Sennello that was designed to accommodate small sample sizes (5) . Briefly, 0.2 ml of buffered plasma is mixed with 0.2 ml of methanol at 0°C. This mixture is permitted to sit on ice for 5 min and is then centrifuged for 3 min in a microcentrifuge at 4°C. The supernatant (50 p.l) is then injected onto a Zorbax BP C-8 column maintained at 30°C with a heater block. The elution solvent, consisting of 95.5% of 0.035 M ammonium acetate, was adjusted to pH 5.2 with acetic acid and 4.5% acetonitrile. Column flow rates are maintained at 1.0 ml/min, and the eluate is monitored at 265 nm. Under these conditions, the peak area was linear with cefsulodin concentrations from 1 to 200 ,ug/ml. The withinday coefficient of variation was 1.3 and the between-day coefficient of variation was 4.4. Cefsulodin recovery from plasma and urine was >95%.
Model-independent techniques were used to describe the biodisposition of cefsulodin (3, 14) . Plasma cefsulodin concentrations for each patient were plotted against time on a semilogarithmic scale. The area under the plasma concentration time curve (AUC) was obtained by using the linear trapezoidal rule up to the final measured plasma concentration and extrapolated to infinity. The elimination half-life where AUMC is the area under the moment curve and T is the infusion duration. The renal clearance (CLR) of cefsulodin for each patient was calculated as CLR = Ac,J AUC0o, where A is the cumulative amount of drug excreted (15) .
RESULTS
Twelve patients ranging in age from 12 to 33 years were enrolled in the study (Table 1) . None of the patients was in (7, 15) . Cystic fibrosis patients appear to display a larger apparent volume of distribution and an increased total body clearance. These data and others (8, 9) support the increased antibiotic dosage requirements for treating acute pulmonary exacerbations in these patients.
In the present investigation, the first-dose pharmacokinetics of cefsulodin were evaluated in patients with cystic fibrosis. Our results for tl2p and V are similar to those reported for unaffected adults with normal renal function (4, 6, 12) . This is in contrast to reports describing the biodisposition of other antibiotics in patients with cystic fibrosis wherein the apparent volume of distribution was larger than in unaffected patients (8, 10, 15 (Table 3 ) are compared with those reported for normal adults (1, 4, 6, 12) , it can be seen that cefsulodin clearance is lower in our cystic fibrosis patients. This suggests that increased 1B-lactam clearance may not be characteristic of patients with cystic fibrosis.
More than 70% of the administered drug was excreted during the 6-h study period in our patients. Previous reports of urinary cefsulodin excretion in adults have revealed 50 to 61% of the dose recovered in 24 h (4, 6, 12) . The difference in recovery most likely relates to differences in sample handling. We optimized urinary recovery by keeping our samples on ice and by adding the stabilizing buffer immediately after the urine was voided.
Arvidsson et al. (1) have reported that the urinary clearance of cefsulodin in cystic fibrosis patients is comparable to that in normal controls, but that the actual renal elimination pathway(s) for cefsulodin is different in patients with cystic fibrosis. The exact mechanism for this difference is unclear, but it appears to result from reduced tubular secretion or increased reabsorption by the kidney or both. The latter may 
